Altamira Therapeutics is a preclinical-stage biopharmaceutical company built around xPhore, a peptide-based nanoparticle platform designed to deliver RNA therapeutics — including siRNA, mRNA, and circular RNA — to tissues outside the liver. The core problem xPhore addresses is that most existing RNA delivery technologies work only for liver-targeted therapies; xPhore is designed to deliver RNA payloads systemically to extrahepatic tissues such as tumors, inflamed joints, or cardiovascular tissue. Altamira's customers are biotech and pharma companies that need a delivery vehicle for their own RNA drug programs, and Altamira licenses xPhore to these partners in exchange for upfront fees, development milestones, and royalties. Altamira also develops two in-house siRNA programs — AM-401 for KRAS-driven cancers and AM-411 for rheumatoid arthritis — with the intent to license them out at or after the IND stage rather than commercialize them independently. These programs serve a dual purpose: generating licensable assets and building the preclinical data package needed to attract additional platform partners. Altamira also holds a 49% stake in Altamira Medica, which markets Bentrio, an OTC nasal spray for allergic rhinitis, and retains AM-125, a nasal betahistine reformulation for vertigo being marketed for out-licensing. Altamira intends to monetize these legacy assets to fund its RNA delivery activities. The company currently generates minimal revenue and funds operations primarily through equity raises.